Lexeo Therapeutics Inc SEC Filings

Lexeo Therapeutics (LXEO): insider transaction disclosed. The company’s Chief Technical Officer filed a Form 4 showing 5,940 shares of common stock acquired on 10/15/2025 at a price of $0. Following this, sales on 10/17/2025 totaled 2,091 shares at a weighted average price of $8.935 and 24 shares at a weighted average price of $9.561, with both ranges detailed in the notes. The filing states the sales represent shares sold to cover tax obligations on the release of RSUs.

After these transactions, the reporting person beneficially owned 64,197 shares directly, which includes 49,687 RSUs, each representing a contingent right to one share of common stock.

Lexeo Therapeutics (LXEO) reported insider activity by its Chief Medical Officer on a Form 4. On 10/15/2025, 9,570 shares of Common Stock were acquired at $0 upon the release of Restricted Stock Units. On 10/17/2025, the officer sold 3,344 shares at a weighted average price of $8.935 and 38 shares at a weighted average price of $9.561; the filing states these sales were to cover tax obligations related to the RSU release.

After the transactions, beneficial ownership was 73,261 shares, which includes 60,546 RSUs.

Lexeo Therapeutics (LXEO) reported insider activity by its Chief Executive Officer and Director. On 10/15/2025, the reporting person acquired 33,000 shares of Common Stock at $0 upon RSU release. On 10/17/2025, shares were sold to cover taxes in open market transactions: 12,985 shares at a weighted average price of $8.935 and 148 shares at a weighted average price of $9.561. Following these transactions, beneficial ownership stands at 242,118 shares, which includes 131,092 RSUs, held directly.

Lexeo Therapeutics priced a public offering of 15,625,000 common shares at $8.00 per share, with underwriters purchasing at $7.52. The company granted a 30‑day option for up to 2,343,750 additional shares. Gross proceeds are expected to be approximately $125 million before fees, with closing targeted for October 20, 2025.

Separately, Lexeo agreed to sell 1,250,015 pre‑funded warrants in a private placement for approximately $10 million; the warrants are immediately exercisable at $0.0001 per share and include a 9.99% beneficial ownership cap, adjustable up to 19.99%. As of September 30, 2025, the company estimated $122.8 million in cash, cash equivalents and investments.

Clinical updates: for LX2006, the FDA indicated openness to an accelerated approval BLA using pooled Phase I/II and pivotal data, contingent on enhanced comparability and nonclinical requirements. For LX2020, nine participants have been dosed; the program has been generally well tolerated with one Grade 3 serious adverse event possibly treatment related. Additional safety and efficacy data are expected in January 2026.

Lexeo Therapeutics (Nasdaq: LXEO) launched a primary offering of 15,625,000 shares of common stock at $8.00 per share, generating gross proceeds of $125.0 million, less $0.48 per share in underwriting discounts. The company also entered a concurrent private placement of pre-funded warrants to purchase 1,250,015 shares for approximately $10.0 million at $7.9999 per warrant. The underwriters have a 30-day option to purchase up to 2,343,750 additional shares at the public price, less discounts.

Lexeo estimates net proceeds of approximately $126.2 million from the offering and concurrent private placement, or approximately $143.8 million if the option is exercised in full, to support operations and development plans. As context, cash, cash equivalents and investments were $122.8 million as of September 30, 2025. Shares outstanding were 54,001,214 as of June 30, 2025.

Lexeo Therapeutics (LXEO) filed a preliminary prospectus supplement for a primary offering of common stock and pre-funded warrants. The pre-funded warrants carry a $0.0001 exercise price, do not expire, and are offered in lieu of shares to certain investors subject to 4.99% or 9.99% beneficial ownership limits. The filing includes a 30‑day underwriters’ option to purchase additional shares.

A concurrent private placement is contemplated with Balyasny Asset Management at the public offering price, contingent on the closing of this offering. Lexeo’s common stock last closed at $8.83 on October 15, 2025, and 54,001,214 shares were outstanding as of June 30, 2025.

Operational updates: the company reported preliminary cash, cash equivalents and investments of $122.8 million as of September 30, 2025. For LX2006 (FA cardiomyopathy), the FDA indicated openness to an accelerated approval BLA using pooled data with enhanced manufacturing comparability for the planned pivotal study. LX2020 (PKP2-ACM) has dosed nine participants across dose cohorts with ongoing safety and efficacy assessments.

Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), reported an acquisition of common stock on 09/12/2025 under the companys 2023 Employee Stock Purchase Plan. The Form 4 shows the purchase of 2,193 shares at a price of $2.644 per share. After this transaction, the reporting person beneficially owns 222,251 shares in total, a position that explicitly includes 131,092 Restricted Stock Units.

The filing is executed by an attorney-in-fact and states the ESPP transaction is exempt under Rule 16b-3(c) and 16b-3(d). No derivative transactions or other disposals are reported on this Form 4.

Richard N. Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), amended a Form 4 to correct previously reported insider sales. The amendment states that on 08/18/2025 Townsend disposed of 1,115 shares of Common Stock at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported disposition, Townsend beneficially owned 220,058 shares, which include 131,092 RSUs. The amended filing clarifies an earlier filing that had incorrectly reported a disposition of 2,735 shares. The amendment is signed by an attorney-in-fact on behalf of the reporting person.